| Sign In to gain access to subscriptions and/or personal tools. |
Leukotriene modifiers in the treatment of asthma in childrenPediatric Dept. II°, University of Naples, Naples, Italy, michele.miraglia{at}unina2.it
Pediatric Dept. II°, University of Naples, Naples, Italy
Pediatric Dept. II°, University of Naples, Naples, Italy
Pediatric Dept. II°, University of Naples, Naples, Italy
Pediatric Dept. University "La Sapienza", Rome, Italy
Dipartimento di Pediatria, Policlinico Santa Maria della Misericordia, Perugia, Italy
Pediatric Dept. II°, University of Naples, Naples, Italy Asthma is one of the most common respiratory disorders in clinical practice, affecting up to 13% of people worldwide. Inflammation is the most important component of asthma and inhaled corticosteroids (ICS) are recommended as the first line controller treatment for patients of all ages. Treatment with corticosteroids is often unable to fully control asthma symptoms and progression. Recently, leukotrienes have come to the forefront of research as they have been found play a pivotal role in the airway inflammatory process, and specific drugs have been developed to target them. Cysteiny leukotriene antagonists (LTRAs) have recently emerged as important therapeutic options that show a large potential clinical utility. Three specific LTRAs are licensed for clinical use: montelukast, zafirlukast and pranlukast, although montelukast is the only drug approved in the paediatric age range. It is well tolerated (although adverse effects such as headaches, abdominal pain, rashes, angioedema, pulmonary eosinophilia and arthralgia have been reported) and shows many positive effects in asthmatic patients. Current Global Initiative for Asthma guidelines recommend LTRAs as: (1) a second choice treatment to ICS for patients with mild persistent asthma, (2) an add-on therapy to reduce the dose of ICS in patients with moderate or severe asthma, due to the different and complementary mechanisms of action of these agents. LTRAs may be particularly appropriate choices in a number of clinical situations, including the following: patients with concomitant rhinitis; patients with viral-induced wheeze; patients with exercise-induced bronchoconstriction (EIB) and, in children aged 2-5 years, to reduce the frequency of asthma exacerbations.
Key Words: airway inflammation • asthma • childhood • leukotrienes • montelukast
This version was published on October
1, 2009 Therapeutic Advances in Respiratory Disease, Vol. 3, No. 5,
245-251 (2009) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
|
 |
Sign In to gain access to subscriptions and/or personal tools.
